Efficacy and safety of EGFR-TKIs in combination with angiogenesis inhibitors as first-line therapy for advanced EGFR-mutant non-small-cell lung cancer: a systematic review and meta-analysis

BACKGROUND: For patients with advanced non-small-cell lung cancer (NSCLC) with EGFR mutations, the suggested course of action is epidermal growth factor receptor-tyrosine kinase inhibitors (EGFR-TKIs). Even with a high disease control rate, a majority of patients develop acquired EGFR-TKIs resistanc...

Descripción completa

Detalles Bibliográficos
Autores principales: Hu, Di, Zhou, Yan-Yan, Ma, Hong-Bo, Tao, Miao-Miao, Huang, Qun-Zhen, Yang, Zhen-Zhou, Zhou, Qi
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2023
Materias:
Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10268338/
https://www.ncbi.nlm.nih.gov/pubmed/37316870
http://dx.doi.org/10.1186/s12890-023-02472-x

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10268338/
https://www.ncbi.nlm.nih.gov/pubmed/37316870
http://dx.doi.org/10.1186/s12890-023-02472-x

Ejemplares similares